Fiche société
Sanofi
Traitements, essais et publications liés.
Traitements30programmes
Essais14liés
Publications29liées
SourceDBlocale
Traitements
30| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| FrexalimabThis is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment. The purpose of this study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with MS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: The study intervention duration will be 48 weeks (12 months) for Parts A and B combined. Optional Part C will last until the initiation of a long term safety study for Frexalimab.The follow up duration after the end of study intervention (in case of discontinuation) will be 6 months. The number of scheduled visits (Parts A and B) will be 17 for participants receiving frexalimab SC or IV, with an on-site visit frequency of every month between Week 4 and Week 24 in Part A, then every 1 to 3 months in Part B, then every 6 months in Part C. Participants discontinuing treatment before the End of Study will have an additional 3 follow-up visits. | SEP | Phase 3 | À vérifier | United States, Belgium, China, Italy, Japan | À vérifier |
| gemfibrozilThis is a Phase 1, single-center, open-label, non-randomized study to assess the effects of CYP2C8 inhibition using gemfibrozil, and CYP3A4 and CYP2C8 induction using rifampicin on the pharmacokinetics of SAR442168 in healthy male participants aged 18 to 45 years. | SEP | Phase 1 | À vérifier | United States | À vérifier |
| MRI contrast-enhancing preparationsThis is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment. The purpose of this study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with MS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: The study intervention duration will be 48 weeks (12 months) for Parts A and B combined. Optional Part C will last until the initiation of a long term safety study for Frexalimab.The follow up duration after the end of study intervention (in case of discontinuation) will be 6 months. The number of scheduled visits (Parts A and B) will be 17 for participants receiving frexalimab SC or IV, with an on-site visit frequency of every month between Week 4 and Week 24 in Part A, then every 1 to 3 months in Part B, then every 6 months in Part C. Participants discontinuing treatment before the End of Study will have an additional 3 follow-up visits. | SEP | Phase 3 | À vérifier | United States, Belgium, China, Italy, Japan | À vérifier |
| rifampicinThis is a Phase 1, single-center, open-label, non-randomized study to assess the effects of CYP2C8 inhibition using gemfibrozil, and CYP3A4 and CYP2C8 induction using rifampicin on the pharmacokinetics of SAR442168 in healthy male participants aged 18 to 45 years. | SEP | Phase 1 | À vérifier | United States | À vérifier |
| SAR441344 IVThis is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: * Study duration: 36 weeks * Treatment duration: 24 weeks * Visit frequency: every 2 weeks | Lupus | Phase 2 | À vérifier | United States, Argentina, Brazil, Chile, Georgia, Greece, Hungary, Italy, … | À vérifier |
| SAR441344 SCThis is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: * Study duration: 36 weeks * Treatment duration: 24 weeks * Visit frequency: every 2 weeks | Lupus | Phase 2 | À vérifier | United States, Argentina, Brazil, Chile, Georgia, Greece, Hungary, Italy, … | À vérifier |
| SAR442257Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: * To characterize the safety profile of SAR442257 * To characterize the pharmacokinetics (PK) profile of SAR442257 * To assess preliminary evidence of antitumor activity | Cancer | Phase 1 | À vérifier | United States, Czechia, Norway, South Korea, Spain | À vérifier |
| SAR446268This is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 55 years old with non-congenital myotonic dystrophy (DM) type 1 (DM1). The purpose of this study is to evaluate the safety and efficacy of SAR446268 in knocking down dystrophia myotonica protein kinase (DMPK) messenger ribonucleic acid (mRNA) levels and improving neuromuscular function in DM1 participants receiving a single intravenous (IV) administration of SAR446268. The study consists of a dose escalation part (Part A) during which single ascending doses of SAR446268 will be evaluated in 3 distinct cohorts and an optional fourth dose cohort. Once a safe and effective dose is identified, additional participants will be treated in Part B, the dose expansion phase of the study. The study duration will be 112 weeks (approximately 2 years) for each participant in Parts A and B respectively and includes an optional pre-screening period, approximately 8-week screening phase and a 104-week follow-up period post-SAR446268 administration. | Myopathies | Phase 1/2 | À vérifier | United States, Argentina, Australia, Canada, Israel, United Kingdom | À vérifier |
| SAR448501This is an open-label, multi-ascending dose (MAD) phase 1 study, with dose expansion at selected doses, in adult patients with select autoimmune rheumatic diseases including systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). The purpose of the study is to identify possible optimal dose(s) by assessing the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary clinical response of SAR448501/DR-0201. The study duration per participant will be a minimum of approximately 13 months, including a screening period of up to 28 days, a treatment period of 71 days, and a follow-up period of 42 weeks. If necessary, participants will continue to have visits after End of Study (EOS) every 4 weeks until peripheral blood B cells return to at least 80% of either the lower limit of normal (LLN) or the participant's baseline value. | Lupus | Phase 1 | Immunomodulation | Australia, Bosnia and Herzegovina, New Zealand, South Africa | À vérifier |
| SAR448851This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive impairment due to AD or mild AD dementia and with evidence of cerebral amyloid pathology. This Phase 2 study has 2 parts: Part A is a randomized, double-blind, parallel-group, placebo-controlled study with SAR448851 oral once daily. Part B is an open-label extension. All participants who complete Part A may continue to Part B. An optional dose 2 cohort will be considered to evaluate the efficacy and safety of SAR448851 dose 2 oral once daily. The study duration will be up to 111 weeks for Part A and B, and up to 63 weeks for the dose 2 cohort. The treatment duration will be up to 96 weeks for Part A and B, and up to 48 weeks for the dose 2 cohort. Up to 160 participants will be included in this study. | Alzheimer | Phase 2 | À vérifier | United States | À vérifier |
| Teriflunomide HMR1726Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary Objective: To assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability progression, MRI lesions, cognitive performance and quality of life To evaluate the safety and tolerability of daily SAR442168 To evaluate pharmacodynamics (PD) of SAR442168 | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, Belgium, Brazil, Canada, Chile, Croatia, Czechia, … | À vérifier |
| TolebrutinibPrimary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168 | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, … | À vérifier |
| TolebrutinibPrimary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168 | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, … | À vérifier |
| TolebrutinibPrimary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168 | SEP | Phase 1 | Ralentissement de la progression | United States | À vérifier |
| TolebrutinibPrimary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168 | SEP | Phase 2 | Ralentissement de la progression | United States, Canada, Czechia, Estonia, France, Netherlands, Russia, Spain, Ukraine | À vérifier |
| TolebrutinibPrimary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168 | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, Belgium, Brazil, Canada, Chile, Croatia, Czechia, France, Germany, Greece, Hungary, India, Israel, Latvia, Netherlands, Norway, Portugal, Puerto Rico, Russia, … | À vérifier |
| TolebrutinibPrimary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168 | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, France, Georgia, Germany, Greece, … | À vérifier |
| TolebrutinibPrimary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168 | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, … | À vérifier |
| TolebrutinibPrimary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168 | SEP | Phase 1 | Ralentissement de la progression | United States | À vérifier |
| TolebrutinibPrimary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168 | SEP | Phase 3 | Ralentissement de la progression | United States, Austria, Belarus, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, Germany, Hong Kong, Italy, Japan, Lithuania, Mexico, Poland, Romania, Russia, Spain, … | À vérifier |
| SAR448851This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive impairment due to AD or mild AD dementia and with evidence of cerebral amyloid pathology. This Phase 2 study has 2 parts: Part A is a randomized, double-blind, parallel-group, placebo-controlled study with SAR448851 oral once daily. Part B is an open-label extension. All participants who complete Part A may continue to Part B. An optional dose 2 cohort will be considered to evaluate the efficacy and safety of SAR448851 dose 2 oral once daily. The study duration will be up to 111 weeks for Part A and B, and up to 63 weeks for the dose 2 cohort. The treatment duration will be up to 96 weeks for Part A and B, and up to 48 weeks for the dose 2 cohort. Up to 160 participants will be included in this study. | Alzheimer | Phase 2 | À vérifier | United States | À vérifier |
| SAR441344 IVThis is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: * Study duration: 36 weeks * Treatment duration: 24 weeks * Visit frequency: every 2 weeks | Lupus | Phase 2 | À vérifier | United States, Argentina, Brazil, Chile, Georgia, Greece, Hungary, Italy, Mauritius, Mexico, Puerto Rico, Russia, Spain, Switzerland, Turkey (Türkiye), Ukraine | À vérifier |
| FrexalimabThis is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment. The purpose of this study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with MS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: The study intervention duration will be 48 weeks (12 months) for Parts A and B combined. Optional Part C will last until the initiation of a long term safety study for Frexalimab.The follow up duration after the end of study intervention (in case of discontinuation) will be 6 months. The number of scheduled visits (Parts A and B) will be 17 for participants receiving frexalimab SC or IV, with an on-site visit frequency of every month between Week 4 and Week 24 in Part A, then every 1 to 3 months in Part B, then every 6 months in Part C. Participants discontinuing treatment before the End of Study will have an additional 3 follow-up visits. | SEP | Phase 3 | À vérifier | United States, Belgium, China, Italy, Japan | À vérifier |
| SAR442257Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: * To characterize the safety profile of SAR442257 * To characterize the pharmacokinetics (PK) profile of SAR442257 * To assess preliminary evidence of antitumor activity | Cancer | Phase 1 | À vérifier | United States, Czechia, Norway, South Korea, Spain | À vérifier |
| SAR446268This is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 55 years old with non-congenital myotonic dystrophy (DM) type 1 (DM1). The purpose of this study is to evaluate the safety and efficacy of SAR446268 in knocking down dystrophia myotonica protein kinase (DMPK) messenger ribonucleic acid (mRNA) levels and improving neuromuscular function in DM1 participants receiving a single intravenous (IV) administration of SAR446268. The study consists of a dose escalation part (Part A) during which single ascending doses of SAR446268 will be evaluated in 3 distinct cohorts and an optional fourth dose cohort. Once a safe and effective dose is identified, additional participants will be treated in Part B, the dose expansion phase of the study. The study duration will be 112 weeks (approximately 2 years) for each participant in Parts A and B respectively and includes an optional pre-screening period, approximately 8-week screening phase and a 104-week follow-up period post-SAR446268 administration. | Myopathies | Phase 1/2 | Thérapie génique | United States, Argentina, Australia, Canada, Israel, United Kingdom | À vérifier |
| SAR448501This is an open-label, multi-ascending dose (MAD) phase 1 study, with dose expansion at selected doses, in adult patients with select autoimmune rheumatic diseases including systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). The purpose of the study is to identify possible optimal dose(s) by assessing the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary clinical response of SAR448501/DR-0201. The study duration per participant will be a minimum of approximately 13 months, including a screening period of up to 28 days, a treatment period of 71 days, and a follow-up period of 42 weeks. If necessary, participants will continue to have visits after End of Study (EOS) every 4 weeks until peripheral blood B cells return to at least 80% of either the lower limit of normal (LLN) or the participant's baseline value. | Lupus | Phase 1 | Immunomodulation | Australia, Bosnia and Herzegovina, New Zealand, South Africa | À vérifier |
| TolebrutinibBTK | Phase 3 | Progression | International, Europe | Échec PPMS : PERSEUS n’a pas montré de ralentissement significatif de la progression dans la SEP primaire progressive. Ne pas extrapoler l’autorisation SPMS à la PPMS. | |
| TolebrutinibBTK | Autorisé UE | Progression | Europe | Autorisation UE pour SPMS non active / sans poussées récentes. Indication distincte de la PPMS. | |
| TolebrutinibBTK | Phase 3 | Progression | International | Données RMS/RRMS à conserver sur une ligne séparée. Ne pas mélanger avec PPMS ni SPMS non active. | |
| FrexalimabAnti-CD40L | Phase 2 / Phase 3 | Immunomodulation | International | Signal positif confirmé dans RMS selon données disponibles ; progressive MS à vérifier séparément. |
Essais cliniques
14| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| SAR448501 | Lupus | Phase 1 | NCT06647069 | A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases | RECRUITING |
| SAR446268 | Myopathies | Phase 1/2 | NCT06844214 | BrAAVe — A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 | RECRUITING |
| SAR442257 | Cancer | Phase 1 | NCT04401020 | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | TERMINATED |
| Frexalimab | SEP | Phase 3 | NCT07325292 | Frexcite — Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | RECRUITING |
| SAR441344 IV | Lupus | Phase 2 | NCT05039840 | APATURA — Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| SAR448851 | Alzheimer | Phase 2 | NCT07688213 | TREMHANCE — A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease | RECRUITING |
| Tolebrutinib | SEP | Phase 3 | NCT04410978 | Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) | COMPLETED |
| Tolebrutinib | SEP | Phase 1 | NCT06064539 | Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects | COMPLETED |
| Tolebrutinib | SEP | Phase 3 | NCT06372145 | A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. | ACTIVE_NOT_RECRUITING |
| Tolebrutinib | SEP | Phase 3 | NCT04458051 | Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) | COMPLETED |
| Tolebrutinib | SEP | Phase 3 | NCT04410991 | Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) | COMPLETED |
| Tolebrutinib | SEP | Phase 2 | NCT03996291 | Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis | COMPLETED |
| Tolebrutinib | SEP | Phase 1 | NCT06106074 | Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants | COMPLETED |
| Tolebrutinib | SEP | Phase 3 | NCT04411641 | Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) | COMPLETED |
Publications
29| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| MRI contrast-enhancing preparations | Bioimaging of sense organs and the central nervous system in extant fishes and reptiles in situ: A review. | Anatomical record (Hoboken, N.J. : 2007) | ||
| MRI contrast-enhancing preparations | Cerebral tuberculoma in pregnancy (Jan 1975-May 2025): a systematic review and descriptive analysis of 33 published cases. | BMC infectious diseases | ||
| Frexalimab | Inhibition of CD40L with Frexalimab in Multiple Sclerosis. | The New England journal of medicine | ||
| Frexalimab | Psychometric validation of PROMIS-Fatigue-MS-8a and MSIS-29v2 questionnaires in relapsing multiple sclerosis participants enrolled in a phase 2 trial of frexalimab. | Multiple sclerosis and related disorders | ||
| Frexalimab | A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent-Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design. | Diabetes, obesity & metabolism | ||
| rifampicin | State of the global tuberculosis epidemic: burden, progress towards WHO End TB Strategy targets and systemic challenges. | The Lancet. Microbe | ||
| rifampicin | Advances in development of tuberculosis vaccines and preventive drug therapies: current pipeline, evidence, and access. | The Lancet. Microbe | ||
| rifampicin | Advances in tuberculosis treatment: novel regimens, new drug pipelines, host-directed therapies, and updated management guidelines. | The Lancet. Microbe | ||
| gemfibrozil | Pharmaceuticals, personal care-products and current-use pesticides: a review of the available data from European seas. | Environmental research | ||
| gemfibrozil | A twin enrichment method based on dual-template molecularly imprinted polymer and dispersive liquid-liquid microextraction for simultaneous determination of two COVID-19 medicines in biological fluids. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences | ||
| Teriflunomide HMR1726 | Real-World, Long-Term Outcomes with Cladribine Tablets Versus Other Oral Treatments Among Patients with Multiple Sclerosis. | Neurology and therapy | ||
| Tolebrutinib | Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis. | Drugs | ||
| rifampicin | Electrospun PLA/PCL Membranes for Sustained Transdermal Rifampicin Delivery: Biocompatibility, Stability, and Antimycobacterial Activity. | Polymers | ||
| rifampicin | Pharmacokinetics and Safety of a Novel Clofazimine Formulation and Dosing Strategy in Children With Rifampicin-resistant Tuberculosis. | The Journal of infectious diseases | ||
| gemfibrozil | Nature-based solutions for nutrient and emerging contaminant reduction in a Mediterranean Ramsar wetland. | Environmental geochemistry and health | ||
| gemfibrozil | Real-world treatment patterns and clinical outcomes of patients with primary biliary cholangitis in the United States. | Journal of comparative effectiveness research | ||
| Teriflunomide HMR1726 | Heterogeneity in Teriflunomide Treatment Arms: A Systematic Review and Meta‑Regression of Randomised Multiple Sclerosis Trials. | CNS drugs | ||
| Tolebrutinib | Tolebrutinib in nonrelapsing SPMS: regulatory divergence and the limits of relapse based labels. | Multiple sclerosis and related disorders | ||
| rifampicin | Catalysing tuberculosis elimination in Indonesia: Health economic and policy insights from the BPaL regimen. | PloS one | ||
| rifampicin | Rare primary bone tuberculosis associated with ruxolitinib therapy: A case report and literature review. | Medicine | ||
| gemfibrozil | PGC-1α mediates ER stress-driven apoptotic signaling during gemfibrozil treatment in glioblastoma. | European journal of pharmacology | ||
| gemfibrozil | Silver(I)-Catalyzed A3-Coupling for the Regioselective Synthesis of 2-Chloro-(Phenylvinyl)imidazo[1,2-a]pyridines and Late-Stage Drug Functionalization. | The Journal of organic chemistry | ||
| Tolebrutinib | Tolebrutinib liver safety: A detailed overview. | Multiple sclerosis and related disorders | ||
| Teriflunomide HMR1726 | Clinical Efficacy and Brain Volumetric Changes in Pediatric-Onset Multiple Sclerosis Under Teriflunomide Treatment. | Journal of child neurology | ||
| Teriflunomide HMR1726 | Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination. | Inflammopharmacology | ||
| Teriflunomide HMR1726 | West Nile Neuroinvasive Disease: Current Management, Emerging Therapies and Future Clinical Trial Priorities. | Reviews in medical virology | ||
| Tolebrutinib | Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-Application to recent real-world cases. | Drug metabolism and disposition: the biological fate of chemicals | ||
| Tolebrutinib | Early Anti-CD20 and CNS Penetrant BTK Inhibition to Enhance OPC-Driven Remyelination in Multiple Sclerosis. | CNS & neurological disorders drug targets | ||
| Tolebrutinib | Emerging Role of BTK Inhibitors in Multiple Sclerosis: From Immunobiology to Clinical Translation. | Brain sciences |